解释Ocrelizumab在Treatment-Naïve复发性MS患者中9年开放标签延长的结果。

{"title":"解释Ocrelizumab在Treatment-Naïve复发性MS患者中9年开放标签延长的结果。","authors":"Olga Ciccarelli, Alan J Thompson","doi":"10.1212/WNL.0000000000210307","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":19256,"journal":{"name":"Neurology","volume":"104 4","pages":"e210307"},"PeriodicalIF":8.5000,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Interpreting the Results of 9-Year Open-Label Extension of Ocrelizumab in Treatment-Naïve Patients With Relapsing MS.\",\"authors\":\"Olga Ciccarelli, Alan J Thompson\",\"doi\":\"10.1212/WNL.0000000000210307\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":19256,\"journal\":{\"name\":\"Neurology\",\"volume\":\"104 4\",\"pages\":\"e210307\"},\"PeriodicalIF\":8.5000,\"publicationDate\":\"2025-02-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1212/WNL.0000000000210307\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/30 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1212/WNL.0000000000210307","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/30 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}